Frontiers in Immunology (Jul 2021)
Impact of Tenascin-C on Radiotherapy in a Novel Syngeneic Oral Squamous Cell Carcinoma Model With Spontaneous Dissemination to the Lymph Nodes
- Caroline Spenlé,
- Caroline Spenlé,
- Caroline Spenlé,
- Thomas Loustau,
- Thomas Loustau,
- Thomas Loustau,
- Hélène Burckel,
- Gilles Riegel,
- Gilles Riegel,
- Gilles Riegel,
- Chérine Abou Faycal,
- Chérine Abou Faycal,
- Chérine Abou Faycal,
- Chengbei Li,
- Chengbei Li,
- Chengbei Li,
- Alev Yilmaz,
- Alev Yilmaz,
- Alev Yilmaz,
- Alev Yilmaz,
- Luciana Petti,
- Fanny Steinbach,
- Fanny Steinbach,
- Fanny Steinbach,
- Constance Ahowesso,
- Constance Ahowesso,
- Constance Ahowesso,
- Camille Jost,
- Camille Jost,
- Camille Jost,
- Nicodème Paul,
- Nicodème Paul,
- Nicodème Paul,
- Raphael Carapito,
- Raphael Carapito,
- Raphael Carapito,
- Georges Noël,
- Georges Noël,
- Fabienne Anjuère,
- Nathalie Salomé,
- Nathalie Salomé,
- Nathalie Salomé,
- Gertraud Orend,
- Gertraud Orend,
- Gertraud Orend,
- Gertraud Orend
Affiliations
- Caroline Spenlé
- INSERM U1109-MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, Strasbourg, France
- Caroline Spenlé
- Université de Strasbourg, Strasbourg, France
- Caroline Spenlé
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Thomas Loustau
- Université de Strasbourg, Strasbourg, France
- Thomas Loustau
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Thomas Loustau
- INSERM U1109, The Tumor Microenvironment Group, Strasbourg, France
- Hélène Burckel
- Institut de Cancérologie de Strasbourg Europe (ICANS), UNICANCER, Paul Strauss Comprehensive Cancer Center, Radiobiology Laboratory, Université de Strasbourg, Strasbourg, France
- Gilles Riegel
- Université de Strasbourg, Strasbourg, France
- Gilles Riegel
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Gilles Riegel
- INSERM U1109, The Tumor Microenvironment Group, Strasbourg, France
- Chérine Abou Faycal
- Université de Strasbourg, Strasbourg, France
- Chérine Abou Faycal
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Chérine Abou Faycal
- INSERM U1109, The Tumor Microenvironment Group, Strasbourg, France
- Chengbei Li
- Université de Strasbourg, Strasbourg, France
- Chengbei Li
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Chengbei Li
- INSERM U1109, The Tumor Microenvironment Group, Strasbourg, France
- Alev Yilmaz
- INSERM U1109-MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, Strasbourg, France
- Alev Yilmaz
- Université de Strasbourg, Strasbourg, France
- Alev Yilmaz
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Alev Yilmaz
- INSERM U1109, The Tumor Microenvironment Group, Strasbourg, France
- Luciana Petti
- Université Côte d’Azur, CNRS, IPMC, Valbonne-Sophia Antipolis, France
- Fanny Steinbach
- Université de Strasbourg, Strasbourg, France
- Fanny Steinbach
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Fanny Steinbach
- INSERM U1109, The Tumor Microenvironment Group, Strasbourg, France
- Constance Ahowesso
- INSERM U1109-MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, Strasbourg, France
- Constance Ahowesso
- Université de Strasbourg, Strasbourg, France
- Constance Ahowesso
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Camille Jost
- INSERM U1109-MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, Strasbourg, France
- Camille Jost
- Université de Strasbourg, Strasbourg, France
- Camille Jost
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Nicodème Paul
- Université de Strasbourg, Strasbourg, France
- Nicodème Paul
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Nicodème Paul
- Platform GENOMAX, INSERM UMR_S 1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, LabEx TRANSPLANTEX, Strasbourg, France
- Raphael Carapito
- Université de Strasbourg, Strasbourg, France
- Raphael Carapito
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Raphael Carapito
- Platform GENOMAX, INSERM UMR_S 1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, LabEx TRANSPLANTEX, Strasbourg, France
- Georges Noël
- Institut de Cancérologie de Strasbourg Europe (ICANS), UNICANCER, Paul Strauss Comprehensive Cancer Center, Radiobiology Laboratory, Université de Strasbourg, Strasbourg, France
- Georges Noël
- Institut de Cancérologie Strasbourg Europe (ICANS), UNICANCER, Department of Radiation Oncology, Strasbourg, France
- Fabienne Anjuère
- Université Côte d’Azur, CNRS, IPMC, Valbonne-Sophia Antipolis, France
- Nathalie Salomé
- Université de Strasbourg, Strasbourg, France
- Nathalie Salomé
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Nathalie Salomé
- INSERM U1109, The Tumor Microenvironment Group, Strasbourg, France
- Gertraud Orend
- INSERM U1109-MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, Strasbourg, France
- Gertraud Orend
- Université de Strasbourg, Strasbourg, France
- Gertraud Orend
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Gertraud Orend
- INSERM U1109, The Tumor Microenvironment Group, Strasbourg, France
- DOI
- https://doi.org/10.3389/fimmu.2021.636108
- Journal volume & issue
-
Vol. 12
Abstract
Radiotherapy, the most frequent treatment of oral squamous cell carcinomas (OSCC) besides surgery is employed to kill tumor cells but, radiotherapy may also promote tumor relapse where the immune-suppressive tumor microenvironment (TME) could be instrumental. We established a novel syngeneic grafting model from a carcinogen-induced tongue tumor, OSCC13, to address the impact of radiotherapy on OSCC. This model revealed similarities with human OSCC, recapitulating carcinogen-induced mutations found in smoking associated human tongue tumors, abundant tumor infiltrating leukocytes (TIL) and, spontaneous tumor cell dissemination to the local lymph nodes. Cultured OSCC13 cells and OSCC13-derived tongue tumors were sensitive to irradiation. At the chosen dose of 2 Gy mimicking treatment of human OSCC patients not all tumor cells were killed allowing to investigate effects on the TME. By investigating expression of the extracellular matrix molecule tenascin-C (TNC), an indicator of an immune suppressive TME, we observed high local TNC expression and TIL infiltration in the irradiated tumors. In a TNC knockout host the TME appeared less immune suppressive with a tendency towards more tumor regression than in WT conditions. Altogether, our novel syngeneic tongue OSCC grafting model, sharing important features with the human OSCC disease could be relevant for future anti-cancer targeting of OSCC by radiotherapy and other therapeutic approaches.
Keywords
- radiotherapy
- oral squamous carcinoma
- tumor microenvironment
- tenascin-C
- syngeneic animal model
- immune suppression